Advanced search
Publication Cover
Future Oncology Volume 19, 2023 - Issue 25
Submit an article Journal homepage
1,109
Views
0
CrossRef citations to date
0
Altmetric
Meta-Analysis

Comparison of tumor-agnostic and tumor-specific clinical oncology trial designs: a systematic review and meta-analysis

Mufiza Farid-Kapadia1 Hoffmann-La Roche Limited,7070 Mississauga Road, Mississauga, ON, L5N 5M8, CanadaORCID Iconhttps://orcid.org/0000-0001-8242-2343View further author information
ORCID Icon,
Madelyn Barton1 Hoffmann-La Roche Limited,7070 Mississauga Road, Mississauga, ON, L5N 5M8, CanadaView further author information
,
Zoe Bider-Canfield1 Hoffmann-La Roche Limited,7070 Mississauga Road, Mississauga, ON, L5N 5M8, CanadaView further author information
,
Parneet K Cheema2 William Osler Health System,2100 Bovaird Drive East, Brampton, ON, L6R 3J7, CanadaView further author information
,
Bishal Gyawali3 Queens University, 15 Arch Street, Kingston, ON, K7L 3L4, CanadaORCID Iconhttps://orcid.org/0000-0001-7444-8594View further author information
ORCID Icon,
Natalie M Nightingale4 IQVIA Solutions Canada,1875 Buckhorn Gate, Mississauga, ON, L4W 5P1, CanadaORCID Iconhttps://orcid.org/0000-0001-9988-216XView further author information
ORCID Icon,
Lidija Latifovic4 IQVIA Solutions Canada,1875 Buckhorn Gate, Mississauga, ON, L4W 5P1, CanadaORCID Iconhttps://orcid.org/0000-0002-8011-7553View further author information
ORCID Icon &
Henry J Conter1 Hoffmann-La Roche Limited,7070 Mississauga Road, Mississauga, ON, L5N 5M8, CanadaCorrespondence[email protected]
View further author information
 show all
Pages 1741-1752 | Received 30 Sep 2022, Accepted 03 May 2023, Published online: 07 Jun 2023

Figures & data

Figure 1. Tumor-specific trials and cohorts included in final analysis.

L1: Level 1; L2: Level 2.

Figure 1. Tumor-specific trials and cohorts included in final analysis.L1: Level 1; L2: Level 2.
Figure 2. Tumor-agnostic trials and cohorts included in final analysis.

L1: Level 1; L2: Level 2; ORR: Objective response rate.

Figure 2. Tumor-agnostic trials and cohorts included in final analysis.L1: Level 1; L2: Level 2; ORR: Objective response rate.
Figure 3. Pooled objective response rates for thyroid cancer.

df: Degree of freedom; GLMM: Generalized linear mixed model.

Figure 3. Pooled objective response rates for thyroid cancer.df: Degree of freedom; GLMM: Generalized linear mixed model.
Figure 4. Pooled objective response rates for non-small-cell lung cancer.

df: Degree of freedom; GLMM: Generalized linear mixed model.

Figure 4. Pooled objective response rates for non-small-cell lung cancer.df: Degree of freedom; GLMM: Generalized linear mixed model.
Figure 5. Pooled objective response rates for melanoma.

df: Degree of freedom; GLMM: Generalized linear mixed model.

Figure 5. Pooled objective response rates for melanoma.df: Degree of freedom; GLMM: Generalized linear mixed model.
Figure 6. Pooled objective response rates, stratified by intervention type.

df: Degree of freedom; GLMM: Generalized linear mixed model.

Figure 6. Pooled objective response rates, stratified by intervention type.df: Degree of freedom; GLMM: Generalized linear mixed model.
Supplemental material

Supplementary Table 1

Download MS Word (471.2 KB)

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.